Telix Pharmaceuticals (TLX) Inventory (2023 - 2025)

Telix Pharmaceuticals (TLX) has reported Inventory for 3 consecutive years, with $37.1 million the latest figure, recorded in Q4 2025.

• Quarterly Inventory rose 37.65% year-over-year to $37.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $37.1 million (up 37.65% YoY) and the FY2025 annual result came in at $37.1 million, up 56.99% from the prior year.
• Inventory rose to $37.1 million in Q4 2025 per TLX's latest filing, from $26.9 million in the prior quarter.
• Over the last five years, Inventory for TLX reached as high as $37.1 million in Q4 2025 and fell as low as $12.2 million in Q4 2023.
• A 3-year average of $25.4 million and a median of $26.9 million in 2024 frame the typical range for Inventory.
• Annual changes were most pronounced in 2024 — Inventory surged 120.36% — and 2025, when it jumped 37.65%.
• Year by year, Inventory stood at $12.2 million in 2023, then jumped by 120.36% to $26.9 million in 2024, then surged by 37.65% to $37.1 million in 2025.
• According to Business Quant data, Inventory over the past three periods registered $37.1 million, $26.9 million, and $12.2 million for Q4 2025, Q4 2024, and Q4 2023 respectively.